REG - GRIT Investment Tst. - Conversion of Loan Notes and TVR

Grit Investment TrustAnnouncement

06/04/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230406:nRSF6660Va&default-theme=true

RNS Number : 6660V  GRIT Investment Trust PLC  06 April 2023

GRIT INVESTMENT TRUST PLC

("GRIT" or the "Company")

Conversion of Loan Notes

GRIT has received conversion notices from noteholders converting £75,035.95
convertible loan notes, issued in July 2021, at a price of 2.5 pence ("CLNs"),
into 3,001,438 Ordinary Shares ("CLN Shares").

An application will be made for the 3,001,438 CLN Shares to be admitted to the
Official List of the UK Listing Authority by way of a Premium Listing
("Admission") and it is expected that Admission will become effective and that
dealing in the CLN Shares will commence on or around 8am on 13 April 2023. The
CLN Shares will rank pari passu with the existing ordinary shares of the
Company.

Following Admission, the Company will have 18,198,295 ordinary shares of
0.025p each in issue, none of which are held in treasury. Therefore, the total
number of voting rights in the Company is 18,198,295.

The above figure of 18,198,295 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure and Transparency
Rules.

The Directors of the Company accept responsibility for the contents of this
announcement.

 

 

 

-ENDS-

For further information, please contact:

 GRIT Investment Trust Plc

 Martin Lampshire

 Tel: +44 (0)   20 3198 2554
 Peterhouse Capital Limited

 Lucy Williams/Duncan Vasey

 Tel: +44 (0)20 7469 0930

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CONSSSFFMEDSEIL